Observou-se um caso de resistência à eritropoetina recombinante humana causada por Ectasia Vascular Antral Gástrica em uma mulher de 40 anos de idade. Abstract. DAL MASO, Rosina Conceição Graçaplena et al. Sex hormones in women on dialysis. Rev. Assoc. Med. Bras. [online]. , vol, n.4, pp . 22 out. Observou-se um caso de resistência à eritropoetina recombinante humana causada por Ectasia Vascular Antral. Gástrica em uma mulher de.
|Published (Last):||6 November 2008|
|PDF File Size:||6.47 Mb|
|ePub File Size:||8.77 Mb|
|Price:||Free* [*Free Regsitration Required]|
The diagnosis of GAVE is based on the clinical history and endoscopic appearance. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: Concomitant administration of NOX-H94 decreased anaemia development Blood albumin observed was 3.
In the skin, EPO enhances wound healing, reduces inflammatory response and increases capillary density in ischaemic regions. Clin J Am Soc Nephrol ;3 1: J Natl Cancer Inst ;93 In this patient some factors were discarded such as autoimmune disease, coagulopathy, evident inflammation, vitamin deficiency, hemolysis, liver or heart disease by physical examination and laboratory tests.
Erythropoietin blocks tumour cells apoptosis and potentiates angiogenesis, with increased tumour growth, metastases and reduction of the radiotherapy response Can J Gastroenterol ; Expression of a homologously recombined erythopoietin-SV40 T antigen fusion gene in mouse liver: Regarding the mechanism of action, it acts as the native EPO, stimulating its receptor.
This patient required blood transfusion for acute blood loss. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells.
Hepcidin inhibition and iron increase can be attributed to both anti-inflammatory activity of heparin, by IL-6 reduction, humqna anti-hepcidin activity through BMP sequestrations Lacombe C, Mayeux P. The etiology of GAVE syndrome remains unknown and has been associated with several disease states, including autoimmune disease e.
Apart from the kidney, EPO mRNA expression was also detected in non-haematopoietic tissues, such as brain neurons and glial cellslungs, heart, bone marrow, spleen, humna follicles, reproductive system, pancreatic islets and osteoblasts 7,8. Hypertension and deep vein thrombosis incidence may also increase and antithrombotic prophylaxis in surgical patients treated with rHu-EPO should be considered Fibromuscular proliferation and capillary ectasia with microvascular thrombosis of the lamina propria form the histological hallmark of GAVE.
Erythropoietin production by distal nephron in normal and familial amyloidotic adult human kidneys. Cellular adaptation to hypoxia: Br J Cancer ;96 5: The human EPO gene, located on chromosome 7 codes for EPO, a protein composed of amino acids, heavily glycosylated, with a molecular mass of about 30 kDa 2. Human, nonhuman primate, and rat pancreatic islets express erythropoietin eritroopoetina.
Pharmacology of darbepoetin alfa. Rabie T, Marti HH. It has other non-erythropoietic biological functions, like mitogenesis and angiogenesis, in part via endothelin-1 induction.
Sign in to the Lens
Recomginante response to erythropoiesis-stimulating agents ESAs may be associated with increased mortality. Best Pract Res Clin Anaesthesiol ;27 1: Erythropoietin after a century of research: Rosenfeld G, Enns R. We observed gastrointestinal blood loss by rectal examination that was positive for melena and the presence of occult blood in the stool in this patient.
This binding blocks hepcidin-induced ferroportin degradation, leading to increased serum iron concentration Am J Hematol ;87 4: Hukana production by peritubular cells occurred under hypoxic conditions, suggesting a different regulation mechanism between the nephrons and peritubular cells 5.
Since its discovery, much has been achieved in the knowledge of the biology of this glycoprotein. We are doing follow-up with endoscopies and treatments with APC to control of bleeding in lesions that tend to recur that is a limitation to the treatment of anemia and resistance to rHuEPO in this patient. The histologic findings are not necessary to confirm the diagnosis but can be helpful.
Regulação da produção da eritropoietina e perspectivas terapêuticas na anemia
Thus, in rebleeding, repeat endoscopy is useful and persistent failure of endoscopic treatment, the surgery is necessary 9 Currently, the pharmacological treatment for anaemia in CKD includes therapy with erythropoiesis stimulating agents ESA and supplementation with iron. However, endoscopy is a method of diagnosis, monitoring and treatment in these patients, but surgical treatment should be considered for patients who do not respond to endoscopic therapy.
Escorcio, Carla Solange de Melo Published: For this proposition, we evaluated two distinct groups, one test group, with 77 patients who made use of rHuEPO for three weeks, and a second control group, with 38 patients who did not use this treatment, totaling people.
Some associated factors such as autoimmune disease, hemolysis, heart and liver disease were discarded on physical examination and complementary tests. Besides CKD anaemia, rHu-EPO is currently indicated for anaemia in patients undergoing elective surgeries and cancer patients with chemotherapyinduced anaemia to reduce blood transfusions Thus, it can be administered every two weeks or every month, during the maintenance phase of treatment Apoptosis prevention of these cells is the main mechanism underlying its function 1.